Information about Trimipramine
Trimipramine is a tricyclic antidepressant used in the therapy of major (endogenous) as well as reactive (exogenous) depression.
Liver safety of Trimipramine
In clinical trials, trimipramine therapy was not associated with an increased rate of elevations in serum aminotransferase levels, and it has yet to be linked to instances of clinically apparent acute liver injury.
Mechanism of action of Trimipramine
Trimipramine (trye mip' ra meen) is a tricyclic antidepressant that is believed to act by enhancing serotonergic and dopaminergic neurotransmission. Like most tricyclic antidepressants, trimipramine is a weak inhibitor of serotonin, norepinephrine and dopamine reuptake, but also has direct antagonist activity for some serotonin and adrenergic receptors. Trimipramine has been shown to alleviate symptoms of depression, both in patients with neurotic or situation depression as well as those with major, endogenous depression. Trimipramine
FDA approval information for Trimipramine
Trimipramine was approved for use in the United States in 1979 and is still clinically available, although now not widely used. Trimipramine is available as capsules of 25, 50 and 100 mg generically and under the brand name Surmontil.
Dosage and administration for Trimipramine
The typical initial dosage in adults is 75 mg daily in divided doses, which can be modified to once daily and increased in total dose based upon efficacy and tolerance to as highly as 150 to 200 mg once daily.
Side effects of Trimipramine
Common side effects are diarrhea, nausea, vomiting, fatigue, drowsiness, headache, insomnia, weight gain and sexual dysfunction. Rare potential side effects include increased suicide risk, cardiac arrhythmias, urinary retention and acute serotonin syndrome.
The following are antidepressant subclasses and drugs